Hociglif-25
Description_Effects
Hociglif-25 contains Empagliflozin 25 mg, an advanced oral anti-diabetic medication used for the effective management of Type 2 Diabetes Mellitus. It belongs to the class of SGLT2 inhibitors (Sodium-Glucose Co-Transporter 2 inhibitors), which help reduce blood glucose levels independently of insulin. Empagliflozin works by blocking the reabsorption of glucose in the kidneys, causing excess sugar to be excreted through the urine. This mechanism not only lowers blood sugar levels but also contributes to weight reduction and a mild decrease in blood pressure, offering additional benefits to patients with metabolic syndrome. Hociglif-25 is particularly beneficial for diabetic patients at high risk of cardiovascular disease, as it has been clinically shown to reduce the risk of heart failure and kidney-related complications. It is typically prescribed when lifestyle changes and other oral medications are insufficient in achieving glycemic targets. The tablet is taken once daily, with or without food. Common side effects may include increased urination, thirst, or urinary tract infections. Adequate hydration and regular medical monitoring are advised during treatment. With its dual role in glycemic control and cardiovascular protection, Hociglif-25 is a valuable choice in the comprehensive management of Type 2 diabetes and its associated risks.
